Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 874

1.

Does recall period matter? Comparing PROMIS® physical function with no recall, 24-hr recall, and 7-day recall.

Condon DM, Chapman R, Shaunfield S, Kallen MA, Beaumont JL, Eek D, Mitra D, Benjamin KL, McQuarrie K, Liu J, Shaw JW, Martin Nguyen A, Keating K, Cella D.

Qual Life Res. 2019 Nov 7. doi: 10.1007/s11136-019-02344-0. [Epub ahead of print]

PMID:
31701432
2.

Development, validation and interpretation of the PROMIS Itch Questionnaire: a patient-reported outcome measure for the quality of life impact of itch.

Silverberg JI, Lai JS, Kantor RW, Dalal P, Hickey C, Shaunfield S, Kaiser K, Correia H, Cella D.

J Invest Dermatol. 2019 Oct 16. pii: S0022-202X(19)33307-X. doi: 10.1016/j.jid.2019.08.452. [Epub ahead of print]

PMID:
31628927
3.

A comparison of computer adaptive tests (CATs) and short forms in terms of accuracy and number of items administrated using PROMIS profile.

Segawa E, Schalet B, Cella D.

Qual Life Res. 2019 Oct 8. doi: 10.1007/s11136-019-02312-8. [Epub ahead of print]

PMID:
31595451
4.

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.

Agarwal N, McQuarrie K, Bjartell A, Chowdhury S, Pereira de Santana Gomes AJ, Chung BH, Özgüroğlu M, Juárez Soto Á, Merseburger AS, Uemura H, Ye D, Given R, Cella D, Basch E, Miladinovic B, Dearden L, Deprince K, Naini V, Lopez-Gitlitz A, Chi KN; TITAN investigators.

Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29.

PMID:
31578173
5.

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, Okamoto A, Moore KN, Efrat Ben-Baruch N, Werner TL, Cloven NG, Oaknin A, DiSilvestro PA, Morgan MA, Nam JH, Leath CA 3rd, Nicum S, Hagemann AR, Littell RD, Cella D, Baron-Hay S, Garcia-Donas J, Mizuno M, Bell-McGuinn K, Sullivan DM, Bach BA, Bhattacharya S, Ratajczak CK, Ansell PJ, Dinh MH, Aghajanian C, Bookman MA.

N Engl J Med. 2019 Sep 28. doi: 10.1056/NEJMoa1909707. [Epub ahead of print]

PMID:
31562800
6.

U.K. utility weights for the EORTC QLU-C10D.

Norman R, Mercieca-Bebber R, Rowen D, Brazier JE, Cella D, Pickard AS, Street DJ, Viney R, Revicki D, King MT; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and the MAUCa Consortium.

Health Econ. 2019 Sep 3. doi: 10.1002/hec.3950. [Epub ahead of print]

PMID:
31482619
7.

Reply by Authors.

Liu G, Andreev VP, Helmuth ME, Yang CC, Lai HH, Smith AR, Wiseman JB, Merion RM, Erickson BA, Cella D, Griffith JW, Gore JL, DeLancey JOL, Kirkali Z; LURN Study Group.

J Urol. 2019 Dec;202(6):1238-1239. doi: 10.1097/01.JU.0000581756.21505.f3. Epub 2019 Aug 30. No abstract available.

PMID:
31469608
8.

Linking the Child Behavior Checklist (CBCL) with the Multidimensional Assessment Profile of Disruptive Behavior (MAP-DB): Advancing a dimensional spectrum approach to disruptive behavior.

Kaat AJ, Blackwell CK, Estabrook R, Burns JL, Petitclerc A, Briggs-Gowan MJ, Gershon RC, Cella D, Perlman SB, Wakschlag LS.

J Child Fam Stud. 2019 Feb;28(2):343-353. doi: 10.1007/s10826-018-1272-4. Epub 2018 Oct 17.

PMID:
31452592
9.

Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease.

Carlozzi NE, Goodnight S, Kratz AL, Stout JC, McCormack MK, Paulsen JS, Boileau NR, Cella D, Ready RE.

J Huntingtons Dis. 2019;8(4):467-482. doi: 10.3233/JHD-190364.

PMID:
31424415
10.
11.

Implementing electronic health record-integrated screening of patient-reported symptoms and supportive care needs in a comprehensive cancer center.

Garcia SF, Wortman K, Cella D, Wagner LI, Bass M, Kircher S, Pearman T, Penedo FJ.

Cancer. 2019 Nov 15;125(22):4059-4068. doi: 10.1002/cncr.32172. Epub 2019 Aug 2.

PMID:
31373682
12.

A New Brief Clinical Assessment of Lower Urinary Symptoms for Women and Men: LURN SI-10.

Cella D, Smith AR, Griffith JW, Kirkali Z, Flynn KE, Bradley CS, Jelovsek JE, Gillespie BW, Helfand BT, Talaty P, Weinfurt KP; and the LURN Study Group.

J Urol. 2019 Jul 31:101097JU0000000000000465. doi: 10.1097/JU.0000000000000465. [Epub ahead of print]

PMID:
31364922
13.

Screening Properties of the Diagnostic Criteria for Cancer-Related Fatigue.

Kuhnt S, Friedrich M, Schulte T, Cella D, Hinz A.

Oncol Res Treat. 2019;42(9):440-447. doi: 10.1159/000501128. Epub 2019 Jul 23.

PMID:
31336371
14.

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC).

Shah R, Botteman M, Solem CT, Luo L, Doan J, Cella D, Motzer RJ.

Clin Genitourin Cancer. 2019 Oct;17(5):356-365.e1. doi: 10.1016/j.clgc.2019.05.010. Epub 2019 May 31.

15.

A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire.

Cella D, Smith AR, Griffith JW, Flynn KE, Bradley CS, Gillespie BW, Kirkali Z, Talaty P, Jelovsek JE, Helfand BT, Weinfurt KP; LURN Study Group.

Neurourol Urodyn. 2019 Aug;38(6):1751-1759. doi: 10.1002/nau.24067. Epub 2019 Jun 21.

PMID:
31225927
16.

Impact of Diabetes on the Symptoms of Breast Cancer Survivors.

Storey S, Cohee A, Gathirua-Mwangi WG, Vachon E, Monahan P, Otte J, Stump TE, Cella D, Champion V.

Oncol Nurs Forum. 2019 Jul 1;46(4):473-484. doi: 10.1188/19.ONF.473-484.

17.

End-of-life measures in Huntington disease: HDQLIFE Meaning and Purpose, Concern with Death and Dying, and End of Life Planning.

Carlozzi NE, Boileau NR, Paulsen JS, Perlmutter JS, Lai JS, Hahn EA, McCormack MK, Nance MA, Cella D, Barton SK, Downing NR.

J Neurol. 2019 Oct;266(10):2406-2422. doi: 10.1007/s00415-019-09417-7. Epub 2019 Jun 12.

PMID:
31190171
18.

Development and Initial Validation of the PROMIS®-Plus-HF Profile Measure.

Ahmad FS, Kallen MA, Schifferdecker KE, Carluzzo KL, Yount SE, Gelow JM, McCullough PA, Kimmel SE, Fisher ES, Cella D.

Circ Heart Fail. 2019 Jun;12(6):e005751. doi: 10.1161/CIRCHEARTFAILURE.118.005751. Epub 2019 Jun 5.

PMID:
31163985
19.

Evaluation of responsiveness and estimation of smallest detectable change and minimal important change scores for the Childhood Atopic Dermatitis Impact Scale.

Gabes M, Chamlin SL, Lai JS, Cella D, Mancini AJ, Apfelbacher CJ.

Br J Dermatol. 2019 May 31. doi: 10.1111/bjd.18204. [Epub ahead of print]

PMID:
31148143
20.

Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis.

Arroyo R, Bury DP, Guo JD, Margolin DH, Melanson M, Daizadeh N, Cella D.

Mult Scler. 2019 May 30:1352458519849796. doi: 10.1177/1352458519849796. [Epub ahead of print]

PMID:
31144568
21.

Use of PROMIS-29® in US Veterans: Diagnostic Concordance and Domain Comparisons with the General Population.

LaVela SL, Etingen B, Miskevics S, Cella D.

J Gen Intern Med. 2019 Aug;34(8):1452-1458. doi: 10.1007/s11606-019-05011-9. Epub 2019 May 29.

PMID:
31144276
23.

Calibration and initial validation of a general self-efficacy item bank and short form for the NIH PROMIS®.

Salsman JM, Schalet BD, Merluzzi TV, Park CL, Hahn EA, Snyder MA, Cella D.

Qual Life Res. 2019 Sep;28(9):2513-2523. doi: 10.1007/s11136-019-02198-6. Epub 2019 May 28.

PMID:
31140041
24.

Retraction Note to: Content validity and psychometric evaluation of functional assessment of chronic illness therapy-fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA.

J Patient Rep Outcomes. 2019 May 28;3(1):32. doi: 10.1186/s41687-019-0125-2.

25.

Symptom Based Clustering of Men in the LURN Observational Cohort Study.

Liu G, Andreev VP, Helmuth ME, Yang CC, Lai HH, Smith AR, Wiseman JB, Merion RM, Erickson BA, Cella D, Griffith JW, Gore JL, DeLancey JOL, Kirkali Z; LURN Study Group.

J Urol. 2019 Dec;202(6):1230-1239. doi: 10.1097/JU.0000000000000354. Epub 2019 May 23.

PMID:
31120372
26.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA.

J Patient Rep Outcomes. 2019 May 20;3(1):30. doi: 10.1186/s41687-019-0115-4.

27.

PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains.

Cella D, Choi SW, Condon DM, Schalet B, Hays RD, Rothrock NE, Yount S, Cook KF, Gershon RC, Amtmann D, DeWalt DA, Pilkonis PA, Stone AA, Weinfurt K, Reeve BB.

Value Health. 2019 May;22(5):537-544. doi: 10.1016/j.jval.2019.02.004.

PMID:
31104731
28.

Establishing a common metric for self-reported anxiety in patients with prostate cancer: Linking the Memorial Anxiety Scale for Prostate Cancer with PROMIS Anxiety.

Victorson D, Schalet BD, Kundu S, Helfand BT, Novakovic K, Penedo F, Cella D.

Cancer. 2019 Sep 15;125(18):3249-3258. doi: 10.1002/cncr.32189. Epub 2019 May 15.

PMID:
31090933
29.

The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncology Group (GOG) study.

Spirtos NM, Enserro D, Homesley HD, Gibbons SK, Cella D, Morris RT, DeGeest K, Lee RB, Miller DS.

Gynecol Oncol. 2019 Jul;154(1):13-21. doi: 10.1016/j.ygyno.2019.03.240. Epub 2019 Apr 30.

PMID:
31053405
30.

Development of the Initial Surveys for the All of Us Research Program.

Cronin RM, Jerome RN, Mapes B, Andrade R, Johnston R, Ayala J, Schlundt D, Bonnet K, Kripalani S, Goggins K, Wallston KA, Couper MP, Elliott MR, Harris P, Begale M, Munoz F, Lopez-Class M, Cella D, Condon D, AuYoung M, Mazor KM, Mikita S, Manganiello M, Borselli N, Fowler S, Rutter JL, Denny JC, Karlson EW, Ahmedani BK, O'Donnell CJ; Vanderbilt University Medical Center Pilot Team, and the Participant Provided Information Committee.

Epidemiology. 2019 Jul;30(4):597-608. doi: 10.1097/EDE.0000000000001028.

PMID:
31045611
31.

Positive Affect and Well-Being in Huntington's Disease Moderates the Association Between Functional Impairment and HRQOL Outcomes.

Ready RE, Boileau NR, Barton SK, Lai JS, McCormack MK, Cella D, Fritz NE, Paulsen JS, Carlozzi NE.

J Huntingtons Dis. 2019;8(2):221-232. doi: 10.3233/JHD-180341.

PMID:
31045519
32.

Interviewer- versus self-administration of PROMIS® measures for adults with traumatic injury.

Kisala PA, Boulton AJ, Cohen ML, Slavin MD, Jette AM, Charlifue S, Hanks R, Mulcahey MJ, Cella D, Tulsky DS.

Health Psychol. 2019 May;38(5):435-444. doi: 10.1037/hea0000685.

PMID:
31045427
33.

PROMIS®: Standardizing the patient voice in health psychology research and practice.

Yount SE, Cella D, Blozis S.

Health Psychol. 2019 May;38(5):343-346. doi: 10.1037/hea0000741.

PMID:
31045415
34.

Can 7 or 30-Day Recall Questions Capture Self-Reported Lower Urinary Tract Symptoms Accurately?

Flynn KE, Mansfield SA, Smith AR, Gillespie BW, Bradley CS, Cella D, Clemens JQ, Helmuth ME, Lai HH, Kirkali Z, Talaty P, Weinfurt KP; LURN Study Group.

J Urol. 2019 Apr 30:101097JU0000000000000310. doi: 10.1097/JU.0000000000000310. [Epub ahead of print]

PMID:
31039099
35.

Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms.

Yanez B, Bouchard LC, Cella D, Sosman JA, Kircher SM, Mohindra NA, Cristofanilli M, Penedo FJ.

Cancer. 2019 Jul 15;125(14):2338-2344. doi: 10.1002/cncr.32030. Epub 2019 Apr 29. No abstract available.

PMID:
31034599
36.

PRO-Bookmarking to Estimate Clinical Thresholds for Patient-reported Symptoms and Function.

Cook KF, Cella D, Reeve BB.

Med Care. 2019 May;57 Suppl 5 Suppl 1:S13-S17. doi: 10.1097/MLR.0000000000001087.

PMID:
30985591
37.

The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME.

Future Oncol. 2019 May;15(15):1683-1695. doi: 10.2217/fon-2018-0951. Epub 2019 Apr 10.

PMID:
30968729
38.

Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.

Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D.

BMC Cancer. 2019 Mar 28;19(1):274. doi: 10.1186/s12885-019-5459-x.

39.

Breast cancer survivors' preferences for mHealth physical activity interventions: findings from a mixed methods study.

Phillips SM, Courneya KS, Welch WA, Gavin KL, Cottrell A, Nielsen A, Solk P, Blanch-Hartigan D, Cella D, Ackermann RT, Spring B, Penedo F.

J Cancer Surviv. 2019 Apr;13(2):292-305. doi: 10.1007/s11764-019-00751-3. Epub 2019 Mar 26.

PMID:
30912011
40.

Development and validation of the caregiver roles and responsibilities scale in cancer caregivers.

Shilling V, Starkings R, Jenkins V, Cella D, Fallowfield L.

Qual Life Res. 2019 Jun;28(6):1655-1668. doi: 10.1007/s11136-019-02154-4. Epub 2019 Mar 18.

41.

Bifactor analysis confirmation of the factorial structure of the Functional Assessment of Cancer Therapy-General (FACT-G).

Peipert JD, Cella D.

Psychooncology. 2019 May;28(5):1149-1152. doi: 10.1002/pon.5062. Epub 2019 Apr 17. No abstract available.

PMID:
30883962
42.

Validity and performance of the Functional Assessment of Cancer Therapy-Bladder (FACT-Bl) among advanced urothelial cancer patients.

Degboe A, Ivanescu C, Rohay JM, Turner RR, Cella D.

Support Care Cancer. 2019 Nov;27(11):4189-4198. doi: 10.1007/s00520-019-04709-0. Epub 2019 Mar 1.

43.

Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.

Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A, Shepherd FA, Leighl NB.

Clin Lung Cancer. 2019 Jul;20(4):231-236. doi: 10.1016/j.cllc.2018.12.010. Epub 2018 Dec 22.

PMID:
30797721
44.

Comprehensive validation of the functional assessment of anorexia/cachexia therapy (FAACT) anorexia/cachexia subscale (A/CS) in lung cancer patients with involuntary weight loss.

Gelhorn HL, Gries KS, Speck RM, Duus EM, Bourne RK, Aggarwal D, Cella D.

Qual Life Res. 2019 Jun;28(6):1641-1653. doi: 10.1007/s11136-019-02135-7. Epub 2019 Feb 22.

PMID:
30796591
45.

Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings.

Galipeau N, Klooster B, Krohe M, Tang DH, Revicki DA, Cella D.

J Patient Rep Outcomes. 2019 Feb 7;3(1):10. doi: 10.1186/s41687-019-0098-1.

46.

The Comprehensive Assessment of Self-Reported Urinary Symptoms: A New Tool for Research on Subtypes of Patients with Lower Urinary Tract Symptoms.

Weinfurt KP, Griffith JW, Flynn KE, Cella D, Bavendam T, Wiseman JB, Andreev VP, Lai HH, Liu AB, Kirkali Z, Cameron AP, Bradley CS; LURN Study Group.

J Urol. 2019 Jun;201(6):1177-1183. doi: 10.1097/JU.0000000000000140.

47.

Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.

Feldman SR, Regnier SA, Chirilov A, Hey F, Gilloteau I, Cella D.

J Am Acad Dermatol. 2019 Jun;80(6):1650-1657. doi: 10.1016/j.jaad.2019.01.039. Epub 2019 Jan 29.

48.

Meaningful differences and validity for the NCCN/FACT-P Symptom Index: An analysis of the ALSYMPCA data.

Beaumont JL, Butt Z, Li R, Cella D.

Cancer. 2019 Jun 1;125(11):1877-1885. doi: 10.1002/cncr.31973. Epub 2019 Jan 28.

PMID:
30690719
49.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M.

Ann Oncol. 2019 Apr 1;30(4):567-574. doi: 10.1093/annonc/mdz016.

PMID:
30689703
50.

Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

Cella D, Wilson H, Shalhoub H, Revicki DA, Cappelleri JC, Bushmakin AG, Kudlacz E, Hsu MA.

J Patient Rep Outcomes. 2019 Jan 24;3(1):5. doi: 10.1186/s41687-019-0094-5. Corrected and republished in: J Patient Rep Outcomes. 2019 May 20;3(1):30. Retraction in: J Patient Rep Outcomes. 2019 May 28;3(1):32.

Supplemental Content

Support Center